7/26/2022 6:16:52 AM
MorphoSys Preliminary Q2 Monjuvi U.S. Net Product Sales $23.3 Mln/EUR 21.7 Mln
6/15/2022 8:43:08 AM
I-Mab Partner MorphoSys Announces License Agreements For Felzartamab And TJ210
6/14/2022 4:09:51 PM
MorphoSys And HIBio Enter Into Equity Participation And License Agreements For Felzartamab And MOR210
6/10/2022 3:30:46 AM
MorphoSys Presents Data From Multiple Analyses Of MANIFEST Study
5/4/2022 4:13:59 PM
MorphoSys AG Q1 Loss/share EUR 3.59 Vs. Loss EUR 1.27 Year Ago
3/16/2022 4:11:55 PM
MorphoSys Q4 Loss/share EUR 11.16 Vs. Loss EUR 0.50 Year Ago
1/7/2022 2:19:31 AM
MorphoSys Posts Preliminary 2021 Monjuvi U.S. Net Product Sales Of $79.1 Mln